TD Cowen Reiterates Buy Rating on Krystal Biotech (KRYS)

August 30, 2024 7:59 AM EDT Send to a Friend
TD Cowen analyst Ritu Baral reiterated a Buy rating and $208.00 price target on Krystal Biotech (NASDAQ: KRYS).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login